Clear Search

Showing 2 results for “Kristensen LE” published 2023.

April 2023

Identificación de Dos Subpoblaciones de Tofacitinib con Diferentes Riesgos Relativos frente a Inhibidores TNF: Un análisis del estudio abierto aleatorizado controlado ORAL Surveillance

Ann Rheum Dis. 2023 doi: 10.1136/ard-2022-223715 Epub ahead of print

Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.


March 2023

Asociaciones entre el Riesgo Cardiovascular y las Tasas de Incidencia de Eventos Cardiovasculares Mayores y Malignidades en Pacientes con Artritis Psoriásica y Psoriasis Recibiendo Tofacitinib

Ther Adv Musculoskelet Dis. 2023 doi: 10.1177/1759720X221149965

Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.